Last reviewed · How we verify
NCT02373267: Adamscreen
Screening of TMA Patients for ADAMTS13 Activity and the Description of Systematic Organ Damage and/or Organ Failure in Different Entities of Thrombotic Microangiopathies (TMA)
trial testing Technozyme in Thrombotic Microangiopathies in 100 participants. Status unknown.
1 February 2017
Quick facts
| Lead sponsor | University of Cologne |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 March 2015 |
| Primary completion | 1 February 2017 |
| Estimated completion | 1 February 2019 |
Drugs / interventions tested
- Technozyme — full drug profile →
Conditions studied
- Thrombotic Microangiopathies — all drugs for Thrombotic Microangiopathies →
Sponsor
University of Cologne
Who can join
18 and older, any sex, with Thrombotic Microangiopathies. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
relative incidences of different entities of TMA
Time frame: at baseline
Sponsor's own description
Screening of TMA patients for ADAMTS13 activity and the description of systemic organ damage and/or organ failure in different entities of thrombotic microangiopathies (TMA)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02373267
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thrombotic Microangiopathies
Currently open trials in the same condition.
- NCT06727669 — Longitudinal Cohort of Thrombosis and Hemostasis Diseases · recruiting
- NCT06291025 — Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune · NA · recruiting
- NCT05634928 — Construction of a Database for TMA · recruiting
- NCT04745195 — Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium · recruiting
Other University of Cologne trials
Trials by the same sponsor.
- NCT07280585 — STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease · Phase 3 · recruiting
- NCT06612515 — Vaccine-induced Immunity in Immunocompromised Patients · recruiting
- NCT06781710 — Analysis of the Epidemiology, Clinical Presentation and Therapy as Well as Therapy-associated Risk of Demyelination Synd · recruiting
- NCT05969431 — Hair Cortisol as Marker of Chronic Stress in Preterm and Term Fathers - Fathair-study · recruiting
- NCT05876221 — Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02373267 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Cologne
- Last refreshed: 20 February 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02373267.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing